

**Regd. Office :**

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

August 21, 2013

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We are pleased to inform that **“Zydus receives final approval for Lansoprazole DR Capsules”** from USFDA in different strengths. Please find attached herewith press release in this regard.

Please bring the information to the notice of the members' of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.



Release

Press Release

Release

Press Release

Zydus receives final approval for Lansoprazole DR Capsules

Ahmedabad, 21 August 2013

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole DR Capsules in different strengths of 15 mg and 30 mg. The drug falls in the anti-ulcerant segment.

The estimated sales in 2012 as per IMS for Lansoprazole DR capsules was USD 501 million.

The group now has 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY 2003-04.
